Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173104 · ClinicalTrials.gov registry record · Early Phase 1
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
A Early Phase 1 study of Brain Tumor and Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04173104: Completed Early Phase 1 study of Brain Tumor and Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04173104 is a Early Phase 1 study of Brain Tumor and Brain Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04173104, a Early Phase 1 study of Brain Tumor and Brain Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
Primary Outcome
\[18F\]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PET/MR with [18F]PARPi
- DRUG [18F]PARPi
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2026-02-05 |
| Phase | Early Phase 1 |
What the finished NCT04173104 record still lists
NCT04173104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 282-participant average among 69 other Brain Tumor trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Brain Tumor appearing as the primary indexed condition, and to 2 interventions - of which PET/MR with [18F]PARPi is the first listed.
NCT04173104 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04173104 about?
NCT04173104 is a clinical study titled "PET and MRI Imaging of Brain Tumors Using [18F]PARPi". This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
What is the current status of trial NCT04173104?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-11-01. Estimated completion is 2026-02-05.
What conditions does trial NCT04173104 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Cancer.
What interventions are being tested in trial NCT04173104?
The interventions under investigation include: PET/MR with [18F]PARPi (DIAGNOSTIC_TEST), [18F]PARPi (DRUG).
Who is sponsoring clinical trial NCT04173104?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04173104 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04173104's enrollment target sits among peer trials
5 70th of 69 the lowest of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
ACTIVE NOT RECRUITING · Early Phase 1
-
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
ACTIVE NOT RECRUITING · Early Phase 1
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI